Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)LeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Amphastar Pharmaceuticals (AMPH) Other Gross PP&E Adjustments (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Other Gross PP&E Adjustments data on record, last reported at $606.7 million in Q3 2025.

  • For Q3 2025, Other Gross PP&E Adjustments rose 8.12% year-over-year to $606.7 million; the TTM value through Sep 2025 reached $606.7 million, up 8.12%, while the annual FY2024 figure was $563.5 million, 7.94% up from the prior year.
  • Other Gross PP&E Adjustments reached $606.7 million in Q3 2025 per AMPH's latest filing, up from $600.4 million in the prior quarter.
  • Across five years, Other Gross PP&E Adjustments topped out at $606.7 million in Q3 2025 and bottomed at $412.1 million in Q4 2021.
  • Average Other Gross PP&E Adjustments over 5 years is $495.7 million, with a median of $485.9 million recorded in 2023.
  • Peak YoY movement for Other Gross PP&E Adjustments: fell 1.56% in 2021, then rose 15.48% in 2024.
  • A 5-year view of Other Gross PP&E Adjustments shows it stood at $412.1 million in 2021, then increased by 9.77% to $452.3 million in 2022, then grew by 15.4% to $522.0 million in 2023, then grew by 7.94% to $563.5 million in 2024, then rose by 7.67% to $606.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Gross PP&E Adjustments were $606.7 million in Q3 2025, $600.4 million in Q2 2025, and $587.2 million in Q1 2025.